Background: Unfortunately, 60% of MDS patients fail to achieve a response to HMAs and 33% of del(5q) patients fail to achieve transfusion independence after lenalidomide.
Introduction: Immunotherapy is an exciting new option to stimulate a "host-vs.-cancer" effect.
Abstracts presented at recent annual meetings of the American Society of Hematology are available online. Follow the links below to search for specific abstracts presented at each annual meeting. Abstracts presented at annual meetings prior to 2004 are not available online.
Background: Current tumor profiling analytics provide some insight into the various molecular abnormalities and their individual consequences on oncogenic signaling.
We recently reported a novel interaction between Bcl-2 and Rac1 and linked that to the ability of Bcl-2 to induce a pro-oxidant state in cancer cells.
There are currently 18 drug classes for the treatment of tuberculosis, including those in the development pipeline.
Background: Given the genomic variability observed across multiple myeloma patients, treatment personalization becomes imperative.
Ruxolitinib/Jakafi is a current front line therapy for JAK2-mediated myelofibrosis.
Targeting specific constellation of molecular abnormalities through predictive simulation modeling may provide a practical therapeutic approach to this complex disease.
The personalization of cancer treatments implies the reconsideration of a one-size-fits-all paradigm.